Shares of CorMedix, Inc. (NYSE:CRMD) recorded 22.22% gain during trading session on December 6th, 2018. The script traded as low as $1.36 and last traded at $1.65. 8.12 million shares changed exchanged hands during trading, a drop of -115.44% from the 30-day average session volume of 3.77M shares. The firm had previously closed at $1.35. The company has $114.09M outstanding shares, price-to-earnings-growth ratio of 376.50 and a beta of 2.29. The company has a RSI of 62.10, ATR of 0.17 and a volatility of 13.05% this week. CRMD has a 52 week low price of $0.17 and a 52 week high price of $2.40.
Investors have identified the tech company CorMedix, Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around 188.25M, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
CorMedix, Inc. (CRMD) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For CRMD, the company has in raw cash 6.62 million on their books with 17.55 million currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on an incline. In terms of their assets, the company currently has 0 total, with 9.5 million as their total liabilities. This figure have given the company a good sense of viability under numerous contexts.
CRMD were able to record 0 as free cash flow during the third quarter of the year, this saw their quarterly net cash flow reduce by 0. In cash movements, the company had a total of 0 as operating cash flow.
Potential earnings growth for CorMedix, Inc. (CRMD)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the third quarter of the year, CorMedix, Inc. recorded a total of 373000 in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 0.84% coming in sequential stages and their sales for the third quarter increasing by 0.98%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 312000 trying to sell their products during the last quarter, with the result yielding a gross income of 60000. This allows shareholders to hold on to 114.09M with the revenue now reading -110 cents per share. This is a figure that is close to analyst’s prediction for their fourth quarter (-0.04 cents a share).
Is the stock of CRMD attractive?
Having a look at the company’s valuation, the company is expected to record -0.14 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on CRMD sounds very interesting.
In related news, Exec VP of Tech Operations ARMSTRONG JR. JOHN L. bought 250,000 shares of the company’s stock in a transaction that recorded on November 29th, 2018. The purchase was performed at an average price of 1.45, for a total value of 363,150. As the purchase deal closes, the Chief Executive Officer ARMSTRONG JR. JOHN L. now bought 21,500 shares of the company’s stock, valued at 26,015. Also, Chief Financial Officer Cook Robert W. bought 25,000 shares of the company’s stock in a deal that was recorded on November 27th, 2018. The shares were bought at an average cost of 1.17 per share, with a total market value of 127,083. Following this completion of disposal, the Chief Executive Officer now holds 3,500 shares of the company’s stock, valued at 4,480. In the last 6 months, insiders have changed their ownership in shares of company stock by 3.50%.
0 out of 2 analysts covering the stock have rated it a Buy, while 1 have maintained a Hold recommendation on CorMedix, Inc. stock. 0 analysts has assigned a Sell rating on the CRMD stock. The 12-month mean consensus price target for the company’s shares has been set at $3.00.